University of Miami Dba Umsponsored Programs — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$47,167	15
2024	Research	$992,878	31
2023	Research	$129,354	14
2021	Research	$7,010	4
2020	Research	$64,851	24
2019	Research	$19,020	5

Breakdown

Who paid Research payments · program years 2019–2025

CSL Behring $1,217,935 79 payments
Exelixis Inc. $27,186 5 payments
United Therapeutics Corporation $13,118 7 payments
Relypsa, Inc. $2,040 2 payments

Studies the money was for Research payments · program years 2019–2025

A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE1116 (4-Factor Prothrombin Complex Concentrate [Kcentra / Beriplex]) to Improve Survival in Patients With Traumatic Injury and Acute Major Bleeding $1,142,288 52 payments
A Double-blind, Randomized-withdrawal, Placebo-controlled Study to Evaluate the Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection in Adult Renal Transplant Recipients $31,557 16 payments
A Phase 2/Phase 3, Multicenter, Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled Adaptive Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis $25,070 6 payments
A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of Cabozantinib XL184) in Subjects with Radioiodine Refractory Differentiated Thyroid Cancer who have Progressed after Prior VEGFR-Targeted Therapy $20,175 1 payment
An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A $19,020 5 payments
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension $13,118 7 payments
A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of Cabozantinib XL184 in Subjects with Radioiodine Refractory Differentiated Thyroid Cancer who have Progressed after Prior VEGFR-Targeted Therapy $7,010 4 payments
Rly5016-208P $2,040 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.